{"id":"r-chop-r-had","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infusion reactions (rituximab)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. The alternating chemotherapy cycles (CHOP and HAD) provide intensive cytotoxic activity with different mechanisms and schedules to overcome chemotherapy resistance. This combination approach is designed to improve efficacy in aggressive lymphomas, particularly in younger or fit patients who can tolerate intensive treatment.","oneSentence":"R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:06.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diffuse large B-cell lymphoma (DLBCL)"},{"name":"Other aggressive B-cell non-Hodgkin lymphomas"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT01865110","phase":"PHASE3","title":"R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-11","conditions":"Mantle Cell Lymphoma","enrollment":623},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT03263026","phase":"PHASE3","title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2018-03-20","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":256},{"nctId":"NCT01902693","phase":"","title":"Prospective HIV Chemotherapy Cohort Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-10","conditions":"HIV, Cancer","enrollment":17},{"nctId":"NCT05874778","phase":"PHASE2","title":"A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-15","conditions":"Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy","enrollment":108},{"nctId":"NCT02531308","phase":"PHASE2","title":"Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2015-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":5},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":"Follicular Non-Hodgkin's Lymphoma","enrollment":807},{"nctId":"NCT04974996","phase":"PHASE1","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)","status":"WITHDRAWN","sponsor":"ADC Therapeutics S.A.","startDate":"2022-02-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT01510184","phase":"PHASE3","title":"Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-04-19","conditions":"Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma","enrollment":79},{"nctId":"NCT01321541","phase":"PHASE3","title":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2011-04-20","conditions":"Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma","enrollment":312},{"nctId":"NCT01410630","phase":"","title":"FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-09-07","conditions":"Lymphoma, Lymphoma, Non-Hodgkin, Large B Cell Diffuse Lymphoma","enrollment":66},{"nctId":"NCT00790036","phase":"PHASE3","title":"Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":742},{"nctId":"NCT00554164","phase":"PHASE3","title":"Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2007-11","conditions":"Lymphoma, High-grade","enrollment":1073},{"nctId":"NCT03045471","phase":"","title":"The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2017-03-01","conditions":"To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rituximab, CHOP","rituximab HD AraC"],"phase":"phase_3","status":"active","brandName":"R-CHOP / R-HAD","genericName":"R-CHOP / R-HAD","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas. Used for Diffuse large B-cell lymphoma (DLBCL), Other aggressive B-cell non-Hodgkin lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}